A Form 483 and a warning letter are not two names for the same thing. One is the start of a conversation. The other is the FDA telling you the conversation didn’t go well.
A Form 483 is issued at the close of an inspection. An investigator hands management a list of objectionable conditions observed on site: a data gap, an unvalidated process, a quality unit that didn’t sign off. It’s field-level, it’s specific, and it carries no legal weight on its own. It’s the inspector’s findings, not the agency’s verdict.
A warning letter is the agency’s verdict. It’s reviewed and signed at the district or center level, it cites specific regulations the company violated, and it’s a formal notice that the FDA considers you out of compliance. It gets posted publicly on FDA.gov, which means customers, investors, and competitors all read it.
The escalation between them is where companies win or lose. In March 2026 the FDA issued its first standalone draft guidance on responding to 483s, recommending a written response within 15 business days so the agency can weigh it before deciding whether to escalate. A strong 483 response, with root-cause analysis and a CAPA plan, can stop a warning letter from ever being written. A weak one, or silence, invites it.
The practical read: a 483 is leverage you still hold. A warning letter is leverage you lost. Tools like Regfo exist because that 15-day window is where the outcome gets decided.
Same inspection can produce both. The gap between them is your response.